|
|
|
|
|
|
|
PMWC 2027 Program Is Live
|
PMWC 2027: The program is live. Explore 15 focused programs spanning next-generation therapeutics, AI and computational medicine, precision diagnostics, and integrated precision medicine. Co-hosted by Stanford, UCSF, and Yale, PMWC features leaders including David Baker, Emmanuelle Charpentier, Andrew Ng, Fei-Fei Li, and Mary-Claire King, January 27-29, 2027, at the Santa Clara Convention Center.
|
|
|
|
|
|
|
|
By Ray Dogum, Chief Editor, Drug Discovery Online
|
The AAPS/BioIVT interactive event made NAM adoption feel less like a science debate and more like a trust-building exercise rooted in use cases, standards, and candid exchange.
|
|
|
|
|
|
Can We Cure Diabetes?
|
|
A conversation with Katy Digovich, Minutia
|
We caught up with Minutia CEO Katy Digovich to discuss engineered iPSC-derived islets intended for transplantation into the forearm, which could make a functional cure for insulin-dependent diabetes broadly accessible.
|
|
|
|
|
|
|
|
|
|
Unlocking miRNA Biomarkers With NGS And Digital PCR
|
|
Webinar | QIAGEN
|
Discover how next-generation sequencing and digital PCR enable miRNA biomarker discovery, as well as best practices for sample prep, data analysis, and assay design to advance RNA research.
|
|
|
|
|
|
|
|
|
|
|
|
Workflow For Chemical Characterization And Database Curation
|
|
Application Note | Revvity Signals Software, Inc.
|
Confident identification of known and unknown compounds starts with smarter LC/MS and GC/MS workflows. See how structure elucidation, verification, and centralized data curation work together.
|
|
|
|
|
|
|
|
|
The RNA-targeted small molecule field is reaching a critical inflection point. Join 80+ leaders at the 9th RNA-Targeted Drug Discovery & Development Summit, the only conference dedicated exclusively to RNA-targeted small molecules. Hear the latest advances from Remix Therapeutics, ReviR Therapeutics, AstraZeneca, and Sanofi, explore emerging modalities including RNA degraders and epitranscriptomic approaches, and discover strategies to address selectivity, functional modulation, and target validation challenges as programs advance toward the clinic.
|
|
|
|
|
|
|
|
|
